©2024 Stanford Medicine
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
Not Recruiting
Trial ID: NCT01233479
Purpose
RATIONALE: Studying samples of blood in the laboratory from patients receiving radiation
therapy and chemotherapy may help doctors learn more about the effects of this treatment on
cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers in blood samples from young patients with
newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy.
Official Title
Immunologic Profile of Patients With Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- Histologically confirmed posterior fossa tumor
- Newly diagnosed disease
- Medulloblastoma OR non-medulloblastoma (pilocytic astrocytoma, ependymoma,
atypical rhabdoid tumor, or others)
- Scheduled to undergo craniotomy and tumor resection
- Chiari malformation
- Requires craniectomy for decompression
- No secondary decompression
PATIENT CHARACTERISTICS:
- No unexplained febrile illness
- No active infection
- No autoimmune disorders such as inflammatory bowel disease, juvenile rheumatoid
arthritis, or systemic lupus erythematosus
- No other immunosuppressive disorders (e.g., HIV infection)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Intervention(s):
drug: systemic chemotherapy
other: laboratory biomarker analysis
procedure: therapeutic surgical procedure
radiation: radiation therapy
drug: systemic chemotherapy
other: laboratory biomarker analysis
procedure: therapeutic surgical procedure
radiation: radiation therapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Hematology/Oncology
650-723-5535